TORONTO--(BUSINESS WIRE)--Dec. 1, 2025-- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) (FRA: 20MP) is pleased to provide an update on recent Agrarius™ agricultural product trial results, including key outcomes from its ongoing citrus field trials in Brazil and cattle pasture grass trials in Colombia. These trial programs are intended to support the Company’s customer product adoption strategy and commercial development initiatives for its licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health.

Positive Results Observed in Brazil Citrus Trials

MVMD has been working with a client-directed third-party agricultural partner, FARMATAC, in Brazil to assess the impact of the application of the Agrarius product on mature citrus orchards. FARMATAC has extensive experience designing and managing advanced citrus trials and has completed evaluations on two key varieties of oranges in mature orchards: Hamlin and Valencia.

• Hamlin Variety: Agrarius-treated orchards demonstrated improved plant condition and a productivity increase of approximately 125 boxes (15%) per hectare. Juice yield analysis showed that the treated oranges required 20 fewer boxes to produce one ton of juice compared to the control, resulting in an approximate total yield increase of 22%. Independent agronomists also observed a visual reduction in symptoms associated with Huanglongbing (HLB), also known as citrus greening disease.
• Valencia Variety: The Agrarius-treated block achieved an average of 835 boxes per hectare, compared to 559 boxes in the control, reflecting a 49% yield increase. Treated trees also exhibited stronger vigor and canopy density, consistent with improved nutrient uptake and photosynthetic activity.

Two additional trials are nearing completion in younger citrus orchards, with preliminary observations appearing consistent or more favorable than the mature tree trials. Results from these trials are expected in the coming weeks.

The Company believes that one of the most compelling results from its Brazil citrus trials is the observed reduction in visible symptoms of HLB, a chronic bacterial disease devastating global citrus production.* This aligns with previously disclosed citrus trials the Company conducted earlier in 2024.

“HLB has devastated citrus production globally, and we continue to see the United States Department of Agriculture state that there is no known cure available to producers,” said Dennis Hancock, President and CEO of MVMD. “The early results we are seeing in Brazil are consistent with prior trials we have conducted and, if sustained across broader programs, suggest that Agrarius could represent the first scalable organic tool to help mitigate the impact of citrus greening disease while simultaneously improving orchard productivity and plant health.”

Advancing Pasture Grass Productivity Across Colombia

In Colombia, the Company is nearing completion of a large-scale pasture grass evaluation in partnership with FEDEGAN, the national cattle growers’ federation representing approximately 43 million hectares of pastureland. The study is led by The National University of Colombia in collaboration with MVMD’s agronomists and spans seven distinct livestock regions selected to test the Agrarius technology across varying climates, altitudes, and grass varieties.

The study is focused on productivity, nutritional content, and pasture regrowth performance. Preliminary results have demonstrated improved vegetation health, faster regrowth enabling earlier grazing, and enhanced pasture quality—validated through OneSoil satellite analysis and feedback from technical field teams. Laboratory testing by the Colombian Corporation of Agricultural Research (Agrosavia) further confirmed improved nutritional properties in Agrarius-treated grass. The results suggest that Agrarius may contribute to better feed efficiency, increased milk production, and the potential to support greater cattle density per hectare.

This trial is expected to be finalized by the end of 2025, with final analysis anticipated in early 2026. The Company believes the results position Agrarius as a promising pasture improvement technology for the broader livestock sector.

Broad Crop Validation Supporting Commercial Expansion Objectives

In addition to the citrus and pasture results, Agrarius trials conducted in partnership with universities, private agronomy labs, and farmer networks this year include:

• Corn: Trials by UNESP in Brazil showed yield gains of 14.8% and 11.2% in Dourados and Santa Cruz respectively, attributed to improved root development and higher chlorophyll levels, indicating enhanced nutrient uptake and photosynthetic efficiency.
• Sugarcane: Agroquatro trials showed yield improvements of 8–12 tons/ha (approx. 10%), 15% higher sugar content, and 47% reduction in pest damage. Separate clone seedling trials demonstrated notably faster initial development, including enhanced root mass and shoot emergence, which are key markers for early establishment success and long-term productivity. These benefits are especially relevant for large-scale replanting programs, where improved rooting and early growth can reduce crop failure risk and accelerate harvest timelines.
• Soybeans: In 14 Brazilian farmer trials, Agrarius boosted yields by an average of 6.34 sacs/ha. A CESB Competition entrant achieved a 15.61% increase (117.93 vs. 102 sacs/ha). UNESP lab trials confirmed enhanced carboxylation efficiency, chlorophyll content, and lower oxidative stress, supporting improved plant metabolism under field conditions.
• Cotton: UNESP and FEPAF trials showed a 14.7% increase in cotton bolls per plant and a 7% yield increase, attributed to more efficient photosynthesis and improved water use, particularly relevant in regions with variable rainfall.
• Potatoes: 2025 summer harvest trials showed an 18.49% productivity increase (51,250 vs. 43,250 Kg/Ha), reinforcing the consistent performance of Agrarius across tuber crops and contributing to higher marketable yields.

“Whether in commercial-scale citrus orchards, staple row crops, or forage systems, the efficacy of Agrarius’ performance appears to be reinforcing confidence among our partners,” said Hancock. “We see these results as critical as we work to advance a scaled commercialization pathway across multiple agricultural verticals.”

“The results we are seeing from Agrarius trials in Latin America confirm to us its performance in diverse real-world conditions,” continued Hancock. “We expect that completing effective Agrarius trials helps build the confidence needed for larger agricultural operators to successfully integrate Agrarius more broadly into their operations.”

The Company has initiated additional trials on cotton, coffee, and citrus, along with a second cycle for sugarcane and farmer-led evaluations for wheat and barley. Data from these trials is expected ongoing throughout 2026.

References
* - United States Department of Agriculture, Animal and Plant Health Inspection Service. (n.d.). Citrus Greening. Retrieved February 16, 2024, from https://www.aphis.usda.gov/aphis/ourfocus/planthealth/plant-pest-and-disease-programs/pests-and-diseases/citrus/citrus-greening

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.

Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:

• patented Quicksome™ oral formulation and delivery technologies,
• patented Quicksol™ solubility formulation technology
• licensed product reseller of Agrarius™, a novel agricultural plant signaling technology

Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

MVMD’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

For more Company information and contact details, visit www.MVMD.com.

SOURCE: Mountain Valley MD Holdings Inc.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.

The Company is making forward-looking statements, including but not limited to: continuing trials and their impact on customer integration of the product; impact of the product on crops; and future trials.

The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC has reviewed or approved the contents of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251201073625/en/

For further information:
Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Investor Relations @ 647-725-9755
Email: info@mvmd.com
www.MVMD.com

Source: Mountain Valley MD Holdings Inc.